Tivic Health Systems, Inc. (TIVC)
Tivic Health Systems, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in San Antonio, TX, US. The stock last traded at $0.26, down 10.46% on the session, giving a market capitalisation of $279,155. On trailing twelve-month figures it carries a trailing P/E of -0.04, a net margin of 19397.1%. Its beta of 1.84 implies it has historically moved more than the broad market.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
Tivic Health Systems, Inc. is most often compared with the following Healthcare names: